| Literature DB >> 24551453 |
Abstract
The medical community suffered three significant fish oil failures/setbacks in 2013. Claims that fish oil's EPA/DHA would stop the progression of heart disease were crushed when The Risk and Prevention Study Collaborative Group (Italy) released a conclusive negative finding regarding fish oil for those patients with high risk factors but no previous myocardial infarction. Fish oil failed in all measures of CVD prevention-both primary and secondary. Another major 2013 setback occurred when fish oil's DHA was shown to significantly increase prostate cancer in men, in particular, high-grade prostate cancer, in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) analysis by Brasky et al. Another monumental failure occurred in 2013 whereby fish oil's EPA/DHA failed to improve macular degeneration. In 2010, fish oil's EPA/DHA failed to help Alzheimer's victims, even those with low DHA levels. These are by no means isolated failures. The promise of fish oil and its so-called active ingredients EPA / DHA fails time and time again in clinical trials. This lipids-based physiologic review will explain precisely why there should have never been expectation for success. This review will focus on underpublicized lipid science with a focus on physiology.Entities:
Year: 2014 PMID: 24551453 PMCID: PMC3914521 DOI: 10.1155/2014/495761
Source DB: PubMed Journal: J Lipids ISSN: 2090-3049
Figure 1Cholesteryl ester.
Figure 2Structure and composition of a low-density lipoprotein showing the significance of its esterified cholesterol structure in its center (with permission, Textbook of Medical Physiology (9th edition), page 874, 1996, W. B. Saunders Company).